Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMMAL: Talquetamab and Lenalidomide as Post-ASCT Maintenance in Multiple Myeloma
NCT06461988Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talquetamab in multiple myeloma (MM), sponsored by Stanford University. Primary endpoint: Stringent Complete Response and Complete Response Rate at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06461988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461988.